A Tat antagonist inhibits HIV-1 induction in naturally infected and experimentally infected T cells. |
| |
Authors: | M J Potash G Bentsman G McKinley D J Volsky |
| |
Affiliation: | Molecular Virology Laboratory, St. Lukes/Roosevelt Hospital Center, Columbia University, New York, New York. |
| |
Abstract: | Ro 5-3335, a novel antagonist of human immunodeficiency virus type 1 (HIV-1) Tat activity, inhibits acute and chronic HIV-1 infection in T lymphocytes. Here we describe the effects of Ro 5-3335 on the accumulation of viral DNA during primary infection, the induction of virus from a latently infected cell line, and the expression of virus upon activation of naturally infected T cells. Ro 5-3335 permitted initial DNA synthesis during primary infection, but inhibited the subsequent increase in viral DNA copy number. The induction of HIV-1, as determined by the synthesis of p24 core antigen, was inhibited by 99% by Ro 5-3335 in both the model cell line and naturally infected T cells. |
| |
Keywords: | |
|
|